R&D Trends

Array, Pierre Fabre collaborate on oncology

Monday, November 16, 2015

Array BioPharma and Pierre Fabre are collaborating to globally develop and commercialize Array’s late-stage novel oncology products binimetinib and encorafenib. Binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor, currently are advancing in three global phase III trials for melanoma and ovarian cancer. Top-line results from NEMO, a phase III study of binimetinib in patients with NRAS-mutant melanoma, are anticipated before the end of 2015.

[Read More]

ImmunoCellular, MD Anderson partner on stem cell program

Friday, November 13, 2015

ImmunoCellular Therapeutics has entered into a sponsored research agreement with Dr. Cassian Yee at the University of Texas MD Anderson Cancer Center. Yee is an internationally recognized researcher and leading expert in identifying and isolating cytotoxic T cells. He serves as professor, department of melanoma medical oncology, division of cancer medicine, as well as professor, department of immunology, division of cancer medicine, and director, solid tumor cell therapy, center for cancer immunology research, at MD Anderson.

[Read More]

Heart Association, Google collaborate on heart disease

Thursday, November 12, 2015

The American Heart Association (AHA) and Google Life Sciences (GLS) have announced a joint commitment to form a research collaboration that will bring new, unconventional thinking to one of the longstanding challenges of cardiovascular disease. Each organization will invest $25 million for a total of $50 million over roughly five years to support novel strategies to understand, prevent and reverse coronary heart disease and its consequences, such as heart failure and sudden cardiac death.

[Read More]

Janssen, Hanmi ink diabetes and obesity agreement

Wednesday, November 11, 2015

Janssen Pharmaceuticals has obtained worldwide rights, excluding China and Korea, to develop and commercialize oxyntomodulin-based therapies including HM12525A, a biologic that is completing phase I and expected to enter phase II studies next year, from Hanmi Pharmaceutical. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.

[Read More]